Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8668629 | 0.80 | SLC22A2 (0.37) | EGFRERBB2SLC22A2SLC22A3 | |
| SCHEMBL1355931 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL816702 | 0.79 | TP53 (0.34) | — | |
| SCHEMBL11057354 | 0.76 | TAAR1 (0.45) | — | |
| SCHEMBL2460591 | 0.76 | TDP1 (0.37) | — | |
| SCHEMBL1077660 | 0.75 | KCNH2 (0.38) | — | |
| SCHEMBL9530787 | 0.75 | KMT2A (0.37) | — | |
| SCHEMBL350461 | 0.74 | TSHR (0.38) | — | |
| SCHEMBL2460597 | 0.73 | KCNH2 (0.40) | — | |
| SCHEMBL9800595 | 0.73 | KCNH2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005085863-A2 | BIOMARKER: COMPOUND CORRELATIONS IN CANCER DIAGNOSIS AND THERAPY | APPLIED GENOMICS, INC. (US) | 2005-09-15 | — | — | WO | claimed |
| US-4309428-A | Maytansinoids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-01-05 | — | — | US | claimed |
| EP-0025496-A1 | Maytansinoids, their production and therapeutic compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-03-25 | — | — | EP | claimed |
| US-4193917-A | LACTAM COMPOUND USED AS INTERMEDIATE | GLAXO LABORATORIES, LIMITED (GB) | 1980-03-18 | — | — | US | claimed |
| US-8309554-B2 | Hypoxia activated drugs of nitrogen mustard alkylators | THRESHOLD PHARMACEUTICALS (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | THRESHOLD PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2009140553-A2 | HYPOXIA ACTIVATED DRUGS OF NITROGEN MUSTARD ALKYLATORS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-6433199-B1 | ANTITUMOR, ANTICANCER AGENTS | SHIONOGI BIORESEARCH CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-5969133-A | Bioreductive cytotoxic agents | SHIONGI BIORESEARCH CORP. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | HIF1AN, HIF1A, HYOU1 | EGFR 303/4885ERBB2 201/4885SLC22A2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.